Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2010-10-28 Report Publication Anno…
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Cytos Biotechnology Third Quarter Report 2010
Report Publication Announcement Classification · 95% confidence The document is a short media release (3315 characters) announcing the publication of the 'Third Quarter Report 2010'. It provides a summary of highlights and a financial table, but explicitly directs the reader to a website link to download the 'complete Third Quarter Report'. Per the 'Menu vs Meal' rule, this is an announcement of a report rather than the full report itself, making it a Report Publication Announcement (RPA). 9M 2010
2010-10-28 English
National Institutes of Health, SAIC, and Cytos Biotechnology Collaborate on Malaria Vaccines Research
Earnings Release Classification · 99% confidence The document is a press release dated October 21, 2010, announcing a collaboration between Cytos Biotechnology, NIH, and SAIC regarding malaria vaccine research. It details the nature of the work, quotes the CSO, and provides background information on malaria and the involved entities. The text explicitly states 'Publication of a media release' and ends with a note that 'EquityStory publishes regulatory releases, media releases on the capital market and press releases.' This content is a general corporate announcement about research progress and partnerships, not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial event report (like DIV or CAP). Since it is a general news announcement distributed via a financial news service, the most appropriate classification is the general regulatory/news fallback category, RNS (Regulatory Filings), as it doesn't fit the more specific categories like ER, CT, or IP. FY 2010
2010-10-21 English
Dr. Hans Stocker (61) will resign as EVP Regulatory Affairs of Cytos Biotechnology Ltd at the end of 2010
Board/Management Information Classification · 99% confidence The document is a short press release dated September 28, 2010, announcing that Dr. Hans Stocker will resign as EVP Regulatory Affairs at the end of 2010. This constitutes an announcement of a change in senior management personnel. Based on the definitions, this aligns perfectly with the 'Board/Management Information' category (Code: MANG). The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). It is a specific personnel announcement.
2010-09-28 English
Cytos Biotechnology establishes strong patent position around core technology for CYT003-QbG10 in the treatment of allergic asthma and rhinitis
Regulatory Filings Classification · 85% confidence The document is a press release dated September 28, 2010, announcing recent advances in the company's intellectual property (patent establishment and successful opposition against a third-party patent) related to its lead product CYT003-QbG10. It discusses research updates, intellectual property rights, and partnering discussions, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is a specific announcement about legal/IP status, which doesn't fit neatly into the primary financial reporting categories. Since it is a specific announcement that doesn't match AGM-R, 10-K, ER, IR, or CT, and it is not a management change (MANG) or dividend notice (DIV), the most appropriate general category for specific corporate updates that don't fit elsewhere, especially those concerning legal/IP strategy, is the fallback category, Regulatory Filings (RNS), as it is a general news release about corporate status.
2010-09-28 English
Cytos Biotechnology Presents Novel Toll-Like Receptor 9 Agonist CYT003-QbG10 for the Treatment of Allergic Asthma at the 2010 Annual Conference of the European Respiratory Society
Environmental & Social Information Classification · 99% confidence The document is a press release dated September 21, 2010, announcing that clinical results for a drug candidate (CYT003-QbG10) were presented at the European Respiratory Society conference. It details the study design, key findings (efficacy, safety), and provides background information on the disease, the drug, and the company. This content structure—announcing research findings and clinical updates via a press release—most closely aligns with an Earnings Release (ER) if it were summarizing financial performance, but since it is purely a research/clinical update, it fits best under the general category for non-standard regulatory announcements or research updates. Given the options, it is a specific research update announcement. However, none of the codes perfectly capture a 'Research Update Press Release'. It is not a formal financial report (10-K, IR, ER), nor a presentation (IP), nor a management discussion (MDA). Since it is a news announcement about clinical data presentation, and not a formal regulatory filing like a 10-K or a formal earnings report, the closest fit among the provided options for a significant, non-financial, company-specific announcement that isn't covered elsewhere is often the general Regulatory Filings (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but it reads like a news release. Given the context of presenting research results, and lacking a specific 'Research Update' code, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for this type of corporate news release that isn't a standard financial filing or a formal presentation.
2010-09-21 English
Cytos Biotechnology to Present at the 2010 Annual Conference of the European Respiratory Society in Barcelona, Spain
Environmental & Social Information Classification · 99% confidence The document is a short announcement (3452 characters) titled 'News Details' and explicitly states 'Publication of a media release'. It details that the company will present abstract information at the '2010 Annual Conference of the European Respiratory Society'. This is not a full financial report (like 10-K or IR), nor is it a formal AGM presentation (AGM-R) or a voting result (DVA). It is a general announcement about participation in an external conference, which fits best under the general regulatory/news announcement category, RNS, as it doesn't fit the more specific categories like ER, DIV, or CAP. Given the nature of the content (announcing a presentation at a third-party conference), it is a general regulatory filing/news release.
2010-09-07 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.